Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial
Yuan Zhang(Sun Yat-sen University), Ling‐Long Tang(Sun Yat-sen University), Ying‐Qin Li(Sun Yat-sen University), Yu‐Pei Chen(Sun Yat-sen University), Mei Shi(Xijing Hospital), Xiaojing Du(Sun Yat-sen University), Ye Tian(Soochow University), Guoxian Long(Tongji Hospital), Qiong-Fei Su(First Affiliated Hospital of Guangdong Pharmaceutical University), Zhibin Cheng(L-3 Communications (United States)), Guan‐Qun Zhou(Sun Yat-sen University), Hao‐Yuan Mo(L-3 Communications (United States)), Qiaodan Liu(Sun Yat-sen University), Ying Sun(Key Laboratory of Guangdong Province), Yan Sun(Peking University), Feng Jin(China Medical University), Jing Huang(Sun Yat-sen University), Li Zou(Sun Yat-sen University), Kunyu Yang(Macau University of Science and Technology), Cheng Xu(Sun Yat-sen University), Fei Han(Sun Yat-sen University), Yan‐Ping Mao(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Lei Chen(Zhuzhou Central Hospital), Yuhong Li(Southwest Jiaotong University), Na Liu(Sun Yat-sen University), Ning Zhang(First People's Hospital of Foshan), Jun Ma(Shanghai Institute of Technology), Ling Li(Guangxi Medical University), Xiao‐Dong Zhu(Fudan University Shanghai Cancer Center), Rui Guo(Sun Yat-sen University), Siyang Wang(L-3 Communications (United States)), Wei‐Han Hu(Sun Yat-sen University), Guoqing Hu(Tongji Hospital), Jinhua Long(Guizhou Cancer Hospital), Xicheng Wang(Shanghai East Hospital), Jia‐Wei Lv(Sun Yat-sen University), Shaoqiang Liang(First People's Hospital of Foshan), Jingao Li(Jiangxi Provincial Cancer Hospital), Wen‐Fei Li(Sun Yat-sen University), Jian Zang(Shenyang Agricultural University), Rui Sun(Sun Yat-sen University), Baomin Zheng(Peking University), Yun Xiao(Harbin Medical University), Ying Guo(Sun Yat-sen University), Fang‐Yun Xie(Sun Yat-sen University)
Cited by 147
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934